Terms: = Pancreatic cancer AND PRKAR1A, DKFZp779L0468, 5573, ENSG00000108946, PRKAR1, P10644, CNC1, PKR1, MGC17251, PPNAD1, TSE1, CNC, CAR
331 results:
1. Armored TGFβRIIDN ROR1-car T cells reject solid tumors and resist suppression by constitutively-expressed and treatment-induced TGFβ1.
Tran TM; Chand Thakuri BK; Nurmukhambetova S; Lee JJ; Hu P; Tran NQ; Steimle B; Dash P; Schneider D
J Immunother Cancer; 2024 Apr; 12(4):. PubMed ID: 38609317
[TBL] [Abstract] [Full Text] [Related]
2. Complete remission of advanced pancreatic cancer induced by claudin18.2-targeted car-T cell therapy: a case report.
Zhong G; Zhang X; Guo Z; Gao Y; Zhao B; Liu X; Chen L; Qiao J; Yu C; Wang L; Li Y; Yu L
Front Immunol; 2024; 15():1325860. PubMed ID: 38487523
[TBL] [Abstract] [Full Text] [Related]
3. cancer-oocyte SAS1B protein is expressed at the cell surface of multiple solid tumors and targeted with antibody-drug conjugates.
Mandal A; Shetty J; Tran CA; Olson WC; Mandal M; Ban B; Pires ES; Adair SJ; Bauer TW; Slingluff CL; Herr JC
J Immunother Cancer; 2024 Mar; 12(3):. PubMed ID: 38485187
[TBL] [Abstract] [Full Text] [Related]
4. Ectopic CXCR2 expression cells improve the anti-tumor efficiency of car-T cells and remodel the immune microenvironment of pancreatic ductal adenocarcinoma.
Dai Z; Lin X; Wang X; Zou X; Yan Y; Wang R; Chen Y; Tasiheng Y; Ma M; Wang X; Cheng H; Yu X; Liu C
Cancer Immunol Immunother; 2024 Mar; 73(4):61. PubMed ID: 38430267
[TBL] [Abstract] [Full Text] [Related]
5. Mesothelin antigen density influences anti-mesothelin chimeric antigen receptor T cell cytotoxicity.
Chu GJ; Bailey CG; Nagarajah R; Liang O; Metierre C; Sagnella SM; Castelletti L; Yeo D; Adelstein S; Rasko JEJ
Cytotherapy; 2024 Apr; 26(4):325-333. PubMed ID: 38349311
[TBL] [Abstract] [Full Text] [Related]
6. IL-15-secreting car natural killer cells directed toward the pan-cancer target CD70 eliminate both cancer cells and cancer-associated fibroblasts.
Van den Eynde A; Gehrcken L; Verhezen T; Lau HW; Hermans C; Lambrechts H; Flieswasser T; Quatannens D; Roex G; Zwaenepoel K; Marcq E; Joye P; Cardenas De La Hoz E; Deben C; Gasparini A; Montay-Gruel P; Le Compte M; Lion E; Lardon F; Van Laere S; Siozopoulou V; Campillo-Davo D; De Waele J; Pauwels P; Jacobs J; Smits E; Van Audenaerde JRM
J Hematol Oncol; 2024 Feb; 17(1):8. PubMed ID: 38331849
[TBL] [Abstract] [Full Text] [Related]
7. The role of microbial metabolites in endocrine tumorigenesis: From the mechanistic insights to potential therapeutic biomarkers.
Zhang Y; Tang N; Zhou H; Zhu Y
Biomed Pharmacother; 2024 Mar; 172():116218. PubMed ID: 38308969
[TBL] [Abstract] [Full Text] [Related]
8. New CEACAM-targeting 2A3 single-domain antibody-based chimeric antigen receptor T-cells produce anticancer effects in vitro and in vivo.
Jancewicz I; Śmiech M; Winiarska M; Zagozdzon R; Wisniewski P
Cancer Immunol Immunother; 2024 Jan; 73(2):30. PubMed ID: 38279989
[TBL] [Abstract] [Full Text] [Related]
9. Mucin-1-Targeted Chimeric Antigen Receptor T Cells Are Effective and Safe in Controlling Solid Tumors in Immunocompetent Host.
Zhou R; Wu ST; Yazdanifar M; Williams C; Sanders A; Brouwer C; Maher J; Mukherjee P
J Immunother; 2024 Apr; 47(3):77-88. PubMed ID: 38270462
[TBL] [Abstract] [Full Text] [Related]
10. Tumor resistance to anti-mesothelin car-T cells caused by binding to shed mesothelin is overcome by targeting a juxtamembrane epitope.
Liu XF; Onda M; Schlomer J; Bassel L; Kozlov S; Tai CH; Zhou Q; Liu W; Tsao HE; Hassan R; Ho M; Pastan I
Proc Natl Acad Sci U S A; 2024 Jan; 121(4):e2317283121. PubMed ID: 38227666
[TBL] [Abstract] [Full Text] [Related]
11. Clinical features and long-term outcomes of patients with type 2 autoimmune pancreatitis.
de Pretis N; Carlin M; Calderini E; Caldart F; Conti Bellocchi MC; Amodio A; De Marchi G; Campagnola P; Crinò SF; Bernardoni L; Gabbrielli A; Martinelli L; Frulloni L
United European Gastroenterol J; 2024 Apr; 12(3):319-325. PubMed ID: 38217278
[TBL] [Abstract] [Full Text] [Related]
12. Using Oncolytic Virus to Retask CD19-Chimeric Antigen Receptor T Cells for Treatment of pancreatic cancer: Toward a Universal Chimeric Antigen Receptor T-Cell Strategy for Solid Tumor.
Chen C; Park AK; Monroy I; Ren Y; Kim SI; Chaurasiya S; Priceman SJ; Fong Y
J Am Coll Surg; 2024 Apr; 238(4):436-447. PubMed ID: 38214445
[TBL] [Abstract] [Full Text] [Related]
13. Chimeric Antigen Receptor T Cell Therapy for pancreatic cancer: A Review of Current Evidence.
Czaplicka A; Lachota M; Pączek L; Zagożdżon R; Kaleta B
Cells; 2024 Jan; 13(1):. PubMed ID: 38201305
[TBL] [Abstract] [Full Text] [Related]
14. Clinically relevant orthotopic pancreatic cancer models for adoptive T cell transfer therapy.
Horvat NK; Karpovsky I; Phillips M; Wyatt MM; Hall MA; Herting CJ; Hammons J; Mahdi Z; Moffitt RA; Paulos CM; Lesinski GB
J Immunother Cancer; 2024 Jan; 12(1):. PubMed ID: 38191243
[TBL] [Abstract] [Full Text] [Related]
15. Exhaustion, rather than lack of infiltration and persistence, of car-T cells hampers the efficacy of car-T therapy in an orthotopic PDAC xenograft model.
Takeuchi Y; Wang Y; Sasaki K; Sato O; Tsuchikawa T; Wang L; Amaishi Y; Okamoto S; Mineno J; Hirokawa Y; Hatanaka KC; Hatanaka Y; Kato T; Shiku H; Hirano S
Biomed Pharmacother; 2024 Jan; 170():116052. PubMed ID: 38141280
[TBL] [Abstract] [Full Text] [Related]
16. Prognostic impact of the distance from the root of splenic artery to tumor in the patients with pancreatic body or tail cancer.
Minagawa T; Okamura Y; Sugiura T; Ito T; Yamamoto Y; Ashida R; Ohgi K; Sasaki K; Uesaka K
Pancreatology; 2024 Feb; 24(1):100-108. PubMed ID: 38102055
[TBL] [Abstract] [Full Text] [Related]
17. PAK in pancreatic cancer-Associated Vasculature: Implications for Therapeutic Response.
Ansardamavandi A; Nikfarjam M; He H
Cells; 2023 Nov; 12(23):. PubMed ID: 38067120
[TBL] [Abstract] [Full Text] [Related]
18. Systemic inflammation adversely affects response to anamorelin in patients with pancreatic cancer.
Tsunematsu M; Uwagawa T; Onda S; Shirai Y; Okui N; Matsumoto M; Furukawa K; Haruki K; Ishizaki S; Ikegami T
Support Care Cancer; 2023 Nov; 31(12):732. PubMed ID: 38055066
[TBL] [Abstract] [Full Text] [Related]
19. Natural killer cells for pancreatic cancer immunotherapy: Role of nanoparticles.
Kumar V; Mahato RI
Cancer Lett; 2023 Nov; 579():216462. PubMed ID: 37924937
[TBL] [Abstract] [Full Text] [Related]
20. Co-expression of IL-4/IL-15-based inverted cytokine receptor in car-T cells overcomes IL-4 signaling in immunosuppressive pancreatic tumor microenvironment.
Zhou Y; Farooq MA; Ajmal I; He C; Gao Y; Guo D; Duan Y; Jiang W
Biomed Pharmacother; 2023 Dec; 168():115740. PubMed ID: 37865999
[TBL] [Abstract] [Full Text] [Related]
[Next]
